MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pone.0284399

Медицинская библиотека · PloS one · 2023

Comprehensive review of safety in Experimental Human Pneumococcal Challenge.

Robinson Ryan E, Myerscough Christopher, He Nengjie, Hill Helen, Shepherd Wendi A, Gonzalez-Dias Patricia, Liatsikos Konstantinos, Latham Samuel, Fyles Fred, Doherty Klara, Hazenberg Phoebe, Shiham Fathimath, Mclenghan Daniella, Adler Hugh, Randles Vicki, Zaidi Seher, Hyder-Wright Angela, Mitsi Elena, Burhan Hassan, Morton Ben, Rylance Jamie, Lesosky Maia, Gordon Stephen B, Collins Andrea M, Ferreira Daniela M

ОбзорМетаанализСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Experimental Human Pneumococcal Challenge (EHPC) involves the controlled exposure of adults to a specific antibiotic-sensitive Streptococcus pneumoniae serotype, to induce nasopharyngeal colonisation for the purpose of vaccine research. The aims are to review comprehensively the safety profile of EHPC, explore the association between pneumococcal colonisation and frequency of safety review and describe the medical intervention required to undertake such studies.

METHODS

A single-centre review of all EHPC studies performed 2011-2021. All recorded serious adverse events (SAE) in eligible studies are reported. An unblinded meta-analysis of collated anonymised individual patient data from eligible EHPC studies was undertaken to assess the association between experimental pneumococcal colonisation and the frequency of safety events following inoculation.

RESULTS

In 1416 individuals (median age 21, IQR 20-25), 1663 experimental pneumococcal inoculations were performed. No pneumococcal-related SAE have occurred. 214 safety review events were identified with 182 (12.85%) participants presenting with symptoms potentially in keeping with pneumococcal infection, predominantly in pneumococcal colonised individuals (colonised = 96/658, non-colonised = 86/1005, OR 1.81 (95% CI 1.28-2.56, P = <0.001). The majority were mild (pneumococcal group = 72.7% [120/165 reported symptoms], non-pneumococcal = 86.7% [124/143 reported symptoms]). 1.6% (23/1416) required antibiotics for safety.

DISCUSSION: No SAEs were identified directly relating to pneumococcal inoculation. Safety review for symptoms was infrequent but occurred more in experimentally colonised participants. Most symptoms were mild and resolved with conservative management. A small minority required antibiotics, notably those serotype 3 inoculated.

CONCLUSION

Outpatient human pneumococcal challenge can be conducted safely with appropriate levels of safety monitoring procedures in place.

Для цитирования: Robinson Ryan E, Myerscough Christopher, He Nengjie, Hill Helen, Shepherd Wendi A, Gonzalez-Dias Patricia, Liatsikos Konstantinos, Latham Samuel, Fyles Fred, Doherty Klara, Hazenberg Phoebe, Shiham Fathimath, Mclenghan Daniella, Adler Hugh, Randles Vicki, Zaidi Seher, Hyder-Wright Angela, Mitsi Elena, Burhan Hassan, Morton Ben, Rylance Jamie, Lesosky Maia, Gordon Stephen B, Collins Andrea M, Ferreira Daniela M. Comprehensive review of safety in Experimental Human Pneumococcal Challenge.. PloS one. 2023. DOI: 10.1371/journal.pone.0284399.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.